Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: 436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK,United Kingdom
Tel: +44 (0)1223 226200
Web: http://astx.com/
Astex is the world leader in fragment based drug discovery – the most important advance in drug discovery chemistry in the last 20 years.
Our internal pipeline is currently focused on the discovery and development of products in the therapeutic areas of oncology and virology.
Our pre-eminent position in this field is underlined by:
The productivity of our discovery engine which has helped to deliver seven novel drug candidates into development – five of which are now in clinical trials with another two in preclinical development.
Multiple collaborations in various therapeutic areas with leading pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica and Novartis that collectively have headline potential deal value in excess of $1 billion for Astex.
World-class science that has been published in leading journals such as Nature, Science and the Journal of Medicinal Chemistry, with some of our papers being among the most cited in their field.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
See our Cookie Privacy Policy Here
